Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MSCL.TO
- Price
- 0.75
- Stock movement up
- +0.02 (2.67%)
- Company name
- Satellos Bioscience Inc.
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 135.76M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-31
DIVIDENDS
MSCL.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.75 |
| Daily high | 0.77 |
| Daily low | 0.75 |
| Daily Volume | 37K |
| All-time high | 0.83 |
| 1y analyst estimate | 1.23 |
| Beta | 0.76 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Nov 2025 |
Downside potential
Loading...
Downside potential data
| MSCL.TO | S&P500 | |
| Current price drop from All-time high | -9.64% | -1.10% |
| Highest price drop | -16.87% | -19.00% |
| Date of highest drop | 27 Oct 2025 | 8 Apr 2025 |
| Avg drop from high | -5.03% | -2.76% |
| Avg time to new high | 4 days | 5 days |
| Max time to new high | 18 days | 89 days |
COMPANY DETAILS
Marketcap
135.76M
Marketcap category
Small-cap
Description
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
TORONTO, October 30, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degener...
October 30, 2025
TORONTO, October 21, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degener...
October 21, 2025
TORONTO, October 10, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degener...
October 10, 2025
TORONTO, September 29, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degen...
September 29, 2025
Satellos Bioscience (MSCL.TO) Monday said it has submitted an Investigational New Drug (IND) applica
September 22, 2025
TORONTO, September 22, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degen...
September 22, 2025
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
September 5, 2025
TORONTO, August 21, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
August 21, 2025
TORONTO (AP) — Satellos Bioscience Inc. MSCLF) on Wednesday reported a loss of $4.1 million in its second quarter. On a per-share basis, the Toronto-based company said it had a loss of 2 cents.
August 13, 2025
TORONTO, August 13, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
August 13, 2025
Next page